These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1387 related items for PubMed ID: 25039333

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Combination of Aspartate Aminotranferase and Tumor Necrosis Factor-α as Non Invasive Diagnostic Tools for Non Alcoholic Steatohepatitis (NASH).
    Purnomo HD, Mundhofir FE, Kasno, Sudijanto E, Darmono, Daldiyono, Djokomoeljanto R, Faradz SM.
    Acta Med Indones; 2015 Jan; 47(1):16-23. PubMed ID: 25948763
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease.
    Motamed N, Sohrabi M, Ajdarkosh H, Hemmasi G, Maadi M, Sayeedian FS, Pirzad R, Abedi K, Aghapour S, Fallahnezhad M, Zamani F.
    World J Gastroenterol; 2016 Mar 14; 22(10):3023-30. PubMed ID: 26973398
    [Abstract] [Full Text] [Related]

  • 5. Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study.
    Younes R, Rosso C, Petta S, Cucco M, Marietti M, Caviglia GP, Ciancio A, Abate ML, Cammà C, Smedile A, Craxì A, Saracco GM, Bugianesi E.
    Liver Int; 2018 Apr 14; 38(4):715-723. PubMed ID: 29028281
    [Abstract] [Full Text] [Related]

  • 6. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity.
    Musso G, Gambino R, Cassader M, Pagano G.
    Ann Med; 2011 Dec 14; 43(8):617-49. PubMed ID: 21039302
    [Abstract] [Full Text] [Related]

  • 7. The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease.
    Goh GB, Issa D, Lopez R, Dasarathy S, Dasarathy J, Sargent R, Hawkins C, Pai RK, Yerian L, Khiyami A, Pagadala MR, Sourianarayanane A, Alkhouri N, McCullough AJ.
    J Gastroenterol Hepatol; 2016 May 14; 31(5):995-1000. PubMed ID: 26589761
    [Abstract] [Full Text] [Related]

  • 8. Validation of the non-alcoholic fatty liver disease activity score.
    Hjelkrem M, Stauch C, Shaw J, Harrison SA.
    Aliment Pharmacol Ther; 2011 Jul 14; 34(2):214-8. PubMed ID: 21585409
    [Abstract] [Full Text] [Related]

  • 9. Characteristics and diagnosis of NAFLD/NASH.
    Hashimoto E, Taniai M, Tokushige K.
    J Gastroenterol Hepatol; 2013 Dec 14; 28 Suppl 4():64-70. PubMed ID: 24251707
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD).
    Tasneem AA, Luck NH, Majid Z.
    Trop Doct; 2018 Apr 14; 48(2):107-112. PubMed ID: 29145775
    [Abstract] [Full Text] [Related]

  • 13. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers.
    Kamada Y, Ono M, Hyogo H, Fujii H, Sumida Y, Mori K, Tanaka S, Yamada M, Akita M, Mizutani K, Fujii H, Yamamoto A, Takamatsu S, Yoshida Y, Itoh Y, Kawada N, Chayama K, Saibara T, Takehara T, Miyoshi E.
    Hepatology; 2015 Nov 14; 62(5):1433-43. PubMed ID: 26199205
    [Abstract] [Full Text] [Related]

  • 14. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP, Hernández-Rocha C, Morales C, Vargas JI, Solís N, Pizarro M, Robles C, Sandoval D, Ponthus S, Benítez C, Barrera F, Soza A, Riquelme A, Arrese M.
    Gastroenterol Hepatol; 2017 Nov 14; 40(6):388-394. PubMed ID: 28359548
    [Abstract] [Full Text] [Related]

  • 15. A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease.
    Yilmaz Y, Eren F.
    Eur J Gastroenterol Hepatol; 2014 Nov 14; 26(11):1292-5. PubMed ID: 25171027
    [Abstract] [Full Text] [Related]

  • 16. Non-alcoholic fatty liver disease: spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study.
    Abrigo JM, Shen J, Wong VW, Yeung DK, Wong GL, Chim AM, Chan AW, Choi PC, Chan FK, Chan HL, Chu WC.
    J Hepatol; 2014 Apr 14; 60(4):809-15. PubMed ID: 24291241
    [Abstract] [Full Text] [Related]

  • 17. Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis.
    Sebastiani G, Alshaalan R, Wong P, Rubino M, Salman A, Metrakos P, Deschenes M, Ghali P.
    PLoS One; 2015 Apr 14; 10(6):e0128774. PubMed ID: 26083565
    [Abstract] [Full Text] [Related]

  • 18. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A, Shasthry SM, Agarwal A, Bihari C, Jain P, Jindal A, Sarin S.
    APMIS; 2017 Nov 14; 125(11):962-973. PubMed ID: 29076589
    [Abstract] [Full Text] [Related]

  • 19. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S, Jensen D, Hart J, Mohanty SR.
    Liver Int; 2013 Oct 14; 33(9):1398-405. PubMed ID: 23763360
    [Abstract] [Full Text] [Related]

  • 20. Non-invasive distinction of non-alcoholic fatty liver disease using urinary volatile organic compound analysis: early results.
    Arasaradnam RP, McFarlane M, Daulton E, Westenbrink E, O'Connell N, Wurie S, Nwokolo CU, Bardhan KD, Savage RS, Covington JA.
    J Gastrointestin Liver Dis; 2015 Jun 14; 24(2):197-201. PubMed ID: 26114180
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.